



PRESS RELEASE • PRESS RELEASE • PRESS RELEASE

NEOVACS TO PRESENT AT CHINA BIO PARTNERING FORUM

Company to Highlight Active Immunotherapy Platform Focused on Autoimmune Diseases

Paris and Boston, April 14, 2015 – NEOVACS (Alternext Paris: ALNEV), a leader in active immunotherapies for the treatment of autoimmune diseases, announced today that it has been selected to present at the seventh annual ChinaBio® Partnering Forum 2015 to be held in Shanghai, April 15 and 16, 2015.

This life science industry event is expected to attract over 800 attendees from around the world focused on partnering opportunities and cross-border relationships in China.

Miguel Sieler, CEO of Neovacs, will present recent information on Neovacs' proprietary active immunotherapy platform on April 15, 2015 at 2:30 pm CST (China Standard Time). China has a high prevalence of Systemic Lupus Erythematosus (SLE) or lupus, an autoimmune disease characterized by a significant unmet medical need. Several Chinese pharmaceutical companies have shown interest in the potential for an innovative, affordable biological treatment option, such as Neovacs' lead product candidate, IFN α -Kinoid.

About ChinaBio® Partnering Forum

ChinaBio® Partnering Forum is the premier life science partnering event in China. Held on April 15–16, 2015, in Shanghai, the event will attract over 800 biotech and pharma leaders from around the world along with hundreds of China-based developers of novel technologies for two days of productive partnering. There will also be over 30 speakers and 50 companies participating in panels and workshops as well as one-to-one partnering meetings held throughout the event.

About Neovacs

Created in 1993, Neovacs is today a leading biotechnology company focused on an active immunotherapy technology platform (Kinoids) with applications in autoimmune and/or inflammatory diseases. On the basis of the company's proprietary technology for inducing a polyclonal immune response (covered by five patent families that potentially run until 2032) Neovacs is focusing its clinical development efforts on IFN α -Kinoid, an immunotherapy being developed for the indication of lupus. Neovacs is also conducting preclinical development works on other therapeutic vaccines in the fields of auto-immune diseases, oncology and allergies. The goal of the Kinoid approach is to enable patients to have access to safe treatments with efficacy that is sustained in these life-long diseases.

For more information on Neovacs, please visit www.neovacs.fr.

Contacts

ChinaBio® Group

Jean Meng

China: +86 21 5137 0751

USA: +1 858 926 4566

jean.meng@chinabio.com

NEOVACS – Investor Relations

Nathalie Trépo

+33 (0)1 53 10 93 00

ntrepo@neovacs.com

Investor Relations / Financial Communications – NewCap

Valentine Brouchet / Pierre Laurent

+33 (0)1 44 71 94 94

theradiag@newcap.fr

Investor Relations / Financial Communications Germany – MC Services

Raimund Gabriel

+49-89-210228-30

raimund.gabriel@mc-services.eu

Press / U.S. Inquiries – The Ruth Group

Melanie Sollid-Penton

1.646.536.7023

msollid@theruthgroup.com